Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Astrocyte Proximity Protects Synapses From Human Amyloid-Beta Induced Degeneration in a Mouse Ex Vivo Model of Early Alzheimer's Disease.

The European journal of neuroscience·2026
Same author

Reduced inhibition, bursting, and accelerated oscillations drive early hippocampal hyperactivity in Alzheimer's disease in vivo.

Communications biology·2026
Same author

Confirmation of p-tau Ser356's association with Alzheimer's disease pathology and lowering in response to WZ4003 treatment in brain slice cultures. Reply to: "Phospho-tau Ser356 is mostly confined to pre-NFT neurons in Alzheimer's pathology".

Acta neuropathologica·2025
Same author

Evidence for trans-synaptic propagation of oligomeric tau in human progressive supranuclear palsy.

Nature neuroscience·2025
Same author

Phylogenetic divergence of GABA<sub>B</sub> receptor signaling in neocortical networks over adult life.

Nature communications·2025
Same author

Divergent actions of physiological and pathological amyloid-β on synapses in live human brain slice cultures.

Nature communications·2025
Same journal

It Takes a Village: Patient Satisfaction in a Specialized Atypical Parkinsonism Interdisciplinary Clinic.

Brain and neuroscience advances·2026
Same journal

First, breathe: Rethinking neuroscience engagement at Glastonbury festival.

Brain and neuroscience advances·2026
Same journal

The <i>BNA</i> Festive Symposium 2025 - delivering neuroscience: From synapse to society.

Brain and neuroscience advances·2026
Same journal

The LOAD2 mouse model of late-onset alzheimer's disease exhibits an accelerated onset of locomotor and anxiety deficits.

Brain and neuroscience advances·2026
Same journal

Re-visiting cognitive reserve: The importance of multiple brain measures.

Brain and neuroscience advances·2026
Same journal

Assessing oligodendrocyte and myelin alterations following absence seizures in a rat model of <i>GRIN2B</i> neurodevelopmental disorder.

Brain and neuroscience advances·2025
See all related articles
  1. Home
  3. Alzheimer's Research Uk Research Conference 2026.
  1. Home
  3. Alzheimer's Research Uk Research Conference 2026.

Related Experiment Video

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Alzheimer's Research UK Research Conference 2026.

Elizabeth M Simzer1,2, Jamie A Elliott1,2, Soraya Meftah1,2

  • 1Institute for Neuroscience and Cardiovascular Research, The University of Edinburgh, UK.

Brain and Neuroscience Advances
|June 15, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Dementia research is advancing beyond single solutions, embracing a collaborative, multidimensional approach for precision care. This shift marks a hopeful new era in understanding and treating neurodegenerative diseases.

Keywords:
Alzheimer’s Research UKAlzheimer’s diseasedementia

More Related Videos

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Related Experiment Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Area of Science:

  • Neuroscience
  • Gerontology
  • Biomedical Research

Background:

  • Alzheimer's Research UK's annual conference convened over 700 experts in molecular biology, data science, clinical trials, prevention, and patient engagement.
  • The conference focused on the evolving landscape of dementia research, highlighting a transition from singular therapeutic targets to comprehensive strategies.

Purpose of the Study:

  • To summarize key insights and emerging trends from the Alzheimer's Research UK 2026 annual conference.
  • To underscore the field's move towards a more hopeful and integrated approach to dementia research and care.

Main Methods:

  • The report synthesizes discussions from plenaries, parallel sessions, and expert dialogues held over two days.
  • It captures the collective sentiment and forward-looking perspectives of leading dementia researchers.

Main Results:

  • A significant consensus emerged: dementia research is entering a more optimistic phase.
  • The field is increasingly adopting a multidimensional, collaborative framework rather than seeking a single cure.

Conclusions:

  • Dementia research is progressing towards personalized and precise care strategies.
  • The future of dementia research is characterized by interdisciplinary collaboration and a holistic understanding of the disease.